Rennova-controlled majority backs FOXO (FOXO) Authorized Increase by consent
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
FOXO Technologies Inc. reports that its majority stockholder, Rennova Health, Inc., which is controlled by the Company’s CEO, has approved an Authorized Increase by written consent. As of the March 20, 2026 record date, this majority holder controlled approximately 97.59% of voting rights directly or through proxy. The Company filed a preliminary Information Statement on Schedule 14C and plans to mail a definitive version to stockholders of record, after which the Authorized Increase will become effective 20 days later.
Positive
- None.
Negative
- None.
Insights
Majority owner unilaterally approves Authorized Increase via written consent.
The filing shows that Rennova Health, Inc., controlled by FOXO’s CEO, holds about 97.59% of the company’s voting rights as of the March 20, 2026 record date. This concentration allows it to approve corporate actions without broader shareholder support.
The Authorized Increase, to take effect 20 days after mailing of the definitive Schedule 14C Information Statement, signals potential future capital structure moves, such as additional share issuances. The economic impact for minority holders depends on how any newly authorized shares are ultimately used.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Majority voting control: 97.59% voting rights
Record date: March 20, 2026
Effective period after mailing: 20 days
+1 more
4 metrics
Majority voting control
97.59% voting rights
Held by Rennova Health, Inc. as of March 20, 2026 record date
Record date
March 20, 2026
Determines stockholders entitled to consent and receive Schedule 14C
Effective period after mailing
20 days
Authorized Increase effective 20 days after mailing definitive Schedule 14C
Report date
March 27, 2026
Date of report and earliest event reported
Key Terms
Written Consent, Schedule 14C, Information Statement, record date, +1 more
5 terms
Written Consent regulatory
"approved certain actions by written consent (the “Written Consent”)."
A written consent is a formal, signed document in which shareholders or directors approve a corporate action without holding a live meeting, similar to signing a petition instead of gathering in person. It matters to investors because it can speed decisions, create a clear legal record of approval, and affect control or governance outcomes — for example enabling changes that would otherwise require a vote at a meeting.
Schedule 14C regulatory
"filed a preliminary Information Statement on Schedule 14C with the U.S. Securities"
Schedule 14C is an SEC filing that companies use to send an official information statement to shareholders when they are not asking for proxy votes. It lays out key facts about corporate actions—such as reorganizations, related-party transactions, or changes in governance—so investors can understand what’s happening without being asked to vote, like receiving a detailed neighborhood notice about a rule change rather than a petition. Because it provides formal, regulated disclosure, Schedule 14C helps investors verify claims, weigh potential impacts on ownership or value, and hold management accountable.
Information Statement regulatory
"will mail the definitive Information Statement on Schedule 14C to its stockholders"
An information statement is a formal document companies distribute to investors and the public to explain important facts about a corporate action, transaction, or situation — for example changes in management, business plans, or financial events. It’s like a clear, written notice that lays out what happened and why it matters, helping investors judge risk and make decisions without being asked to vote. Reliable, timely information can affect share prices and investor trust.
record date financial
"fixed March 20, 2026 as the record date (the “Record Date”)"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What corporate action did FOXO (FOXO) disclose in this 8-K?
FOXO disclosed that its majority stockholder approved an Authorized Increase by written consent. This action was taken without a shareholder meeting and will become effective 20 days after the definitive Schedule 14C Information Statement is mailed to stockholders of record.
Who is the majority stockholder of FOXO (FOXO) and how much control do they have?
The majority stockholder is Rennova Health, Inc., which is controlled by FOXO’s CEO. As of the March 20, 2026 record date, Rennova held approximately 97.59% of FOXO’s voting rights directly or through proxy, effectively controlling shareholder decisions.
What is the record date mentioned in the FOXO (FOXO) filing?
The Board set March 20, 2026 as the record date for determining stockholders entitled to execute the written consent and receive the Information Statement. Only holders as of that date will be mailed the Schedule 14C describing the Authorized Increase approval.
When will FOXO’s Authorized Increase become effective?
The Authorized Increase will become effective 20 days after FOXO mails the definitive Information Statement on Schedule 14C to stockholders of record. This timing follows the company’s filing of a preliminary Schedule 14C with the U.S. Securities and Exchange Commission.
What is FOXO (FOXO) filing on Schedule 14C in connection with this action?
FOXO has filed a preliminary Information Statement on Schedule 14C describing the action approved by the majority stockholder. After SEC clearance, FOXO will mail a definitive Schedule 14C to record-date stockholders, explaining the Authorized Increase and related details.